Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314988 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
A Phase 2 study of Spinal Deformity and Spinal Injuries, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 4
- Study locations
NCT02314988 is a Phase 2 study of Spinal Deformity and Spinal Injuries that is actively recruiting participants, run by Columbia University. The registered enrollment target is 252 participants, below the 587-participant average among 7 other Spinal Deformity trials with a reported enrollment target (57% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02314988, a Phase 2 study of Spinal Deformity and Spinal Injuries, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to evaluate the efficacy of topical tranexamic acid to reduce perioperative blood loss, reduction in postoperative drain output and allogenic transfusion requirements. The proposed study will be a prospective, randomized, double-blind (subject, surgeons, investigators, research coordinators) placebo-controlled study. Patients requiring posterior spinal fusion will be enrolled for this study. Furthermore, patients undergoing elective complex deformity surgery will also be enrolled. Both populations of patients will be randomized into two groups. Group I will receive standard of care operative fixation with topical tranexamic acid intervention (test); Group II will receive standard of care operative fixation with normal saline (placebo) intervention. This study will have a 2-year follow-up and will consist of three periods: screening/enrollment phase up to 21 days from the day of injury to the day of randomization and operative intervention, an inpatient data collection period for 4 days postoperative, and then a follow-up period for 2-years postoperative (visits occurring at 16 weeks, 1 year, and 2 year) time points.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Study Locations (4)
California
- University of California San Francisco Medical Center - San Francisco
Kentucky
- Norton Leatherman Spine Center - Louisville
New York
- NYP/The Allen Hospital - CUIMC - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314988
The ClinicalTrials.gov registry entry for NCT02314988 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 587-participant average among 7 other Spinal Deformity trials with a reported enrollment target (57% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Spinal Deformity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02314988 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Kentucky, New York.
Frequently Asked Questions
What is clinical trial NCT02314988 about?
NCT02314988 is a clinical study titled "Tranexamic Acid to Reduce Blood Loss in Spine Surgery". This study is designed to evaluate the efficacy of topical tranexamic acid to reduce perioperative blood loss, reduction in postoperative drain output and allogenic transfusion requirements. The proposed study will be a prospective, randomized, double-blind (subject, surgeons, investigators, resear...
What is the current status of trial NCT02314988?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2020-06-15. Estimated completion is 2026-07.
What conditions does trial NCT02314988 study?
This clinical trial studies the following conditions: Spinal Deformity, Spinal Injuries.
What interventions are being tested in trial NCT02314988?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02314988?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02314988 being conducted?
This trial has 4 study locations across California, Kentucky, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Deformity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Ailliance Post-Market Clinical Study
RECRUITING · NA
-
Tranexamic Acid in Adult Spinal Deformity Surgery
RECRUITING · Phase 3
-
Intraoperative Monitoring for the Lateral Lumbar Interbody Fusion Procedure
RECRUITING
-
Analysis of Pedicle Screw Accuracy to Plan Using Medtronic Mazor Robotic System
ACTIVE NOT RECRUITING · NA
-
Prospective, Multi-Center Adult Spinal Deformity Outcomes Database Registry
ACTIVE NOT RECRUITING
-
Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.